Stockreport

Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress [Yahoo! Finance]

Nuvation Bio Inc. Class A  (NUVB) 
PDF Wainwright analyst Robert Burns reiterated a Buy rating on the stock and set a $10 price target. The Buy rating was issued after Nuvation Bio Inc. (NYSE:NUVB) announced [Read more]